marked.bio

EGFR TKI (brain-penetrant) ยท small molecule

DZD6008

4 active trials, targeting EGFR. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 4 4 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of DZD6008.

  1. Dizal Pharmaceuticals 4

Trials

4 of 4 trials shown

  1. Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

    Recruiting Phase 1/2 Dizal Pharmaceuticals Started 2025Primary completion 2028-06 NCT07079475

    DZD6008sunvozertinibosimertinib FDA EU

    Part B: EGFR sensitizing mutations (Exon19del and/or L858R) with or without T790M/C797S resistance mutations.

    EGFR exon 19 deletion / L858RNon-Small Cell Lung Cancer

  2. DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

    Recruiting Phase 1/2 Dizal Pharmaceuticals Started 2025Primary completion 2027-06 NCT07070440

    DZD6008pemetrexedcarboplatindocetaxel

    Documentation of EGFR sensitizing mutation confirmed by local laboratory.

    EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer

  3. A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

    Recruiting Phase 1 Dizal Pharmaceuticals Started 2025Primary completion 2027-09 NCT06905197

    DZD6008sunvozertinib

    For Part A monotherapy cohorts and all cohorts of Part B, EGFR sensitizing mutations (Exon19del and/or L858R) are required.

    EGFR exon 19 deletion / L858RNon Small Cell Lung Cancer

  4. Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

    Recruiting Phase 1 Dizal Pharmaceuticals Started 2024Primary completion 2027-10 NCT06813365

    DZD6008

    Documentation of EGFR sensitizing mutation (Exon19del and/or L858R) from a local CLIA-certified laboratory (or equivalent).

    EGFR exon 19 deletion / L858RNonsmall-cell Lung Cancer